-
Numinus Administers MDMA To First Volunteer In Clinical Trial Sponsored By MAPS
Wednesday, March 30, 2022 - 3:20pm | 307Read More...Numinus Wellness Inc. (OTCQX: NUMIF), announced that clinical trial MAPPUSX has gotten underway with the enrolling and dosing of the first trial volunteer in Canada. MAPPUSX, which stands for "A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD”, is...


